4.2.3. Chronic pain and LTOT
One planned eight-week open-label non-randomized study with a six-month follow of those with chronic pain on LTOT is ongoing. This study will investigate the effect of psilocybin and psilocybin-assisted therapy in one of two dosing sessions (25mg and 37.5mg) with the first occurring during the period of opioid tapering. [NCT05585229].83